NL293572A - - Google Patents

Info

Publication number
NL293572A
NL293572A NL293572DA NL293572A NL 293572 A NL293572 A NL 293572A NL 293572D A NL293572D A NL 293572DA NL 293572 A NL293572 A NL 293572A
Authority
NL
Netherlands
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication of NL293572A publication Critical patent/NL293572A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NL293572D 1962-06-07 NL293572A (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US200649A US3206470A (en) 1962-06-07 1962-06-07 Novel pyrrolo[1, 2-alpha]indoles

Publications (1)

Publication Number Publication Date
NL293572A true NL293572A (cs)

Family

ID=22742594

Family Applications (1)

Application Number Title Priority Date Filing Date
NL293572D NL293572A (cs) 1962-06-07

Country Status (8)

Country Link
US (1) US3206470A (cs)
AT (1) AT250951B (cs)
BE (1) BE633281A (cs)
BR (1) BR6349521D0 (cs)
DE (1) DE1445422A1 (cs)
ES (1) ES288785A1 (cs)
GB (1) GB1033253A (cs)
NL (1) NL293572A (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4097579A (en) * 1977-03-31 1978-06-27 Syntex (U.S.A.) Inc. 5-(2-Pyrroyl)-1,2-dihydro-3H-pyrrolo 1,2-a!pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4134894A (en) * 1978-05-04 1979-01-16 Warner-Lambert Company Pyrrolo[1,2-a]indole compounds
US4778812A (en) * 1987-06-12 1988-10-18 American Home Products Corporation 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof
EP1515716A2 (en) 2002-04-03 2005-03-23 Astrazeneca AB Indole derivatives having anti-angiogenetic activity
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EA036955B1 (ru) 2008-08-27 2021-01-19 Арена Фармасьютикалз, Инк. Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
CN103221391B (zh) 2010-01-27 2018-07-06 艾尼纳制药公司 (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
SG183416A1 (en) * 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
JP2020507611A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 原発性胆汁性胆管炎の治療のための化合物および方法
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
CN110878099B (zh) * 2019-11-25 2021-11-30 五邑大学 一种吡咯[1,2,α]吲哚生物碱衍生物的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707187A (en) * 1952-07-14 1955-04-26 Upjohn Co Chemical process

Also Published As

Publication number Publication date
AT250951B (de) 1966-12-12
DE1445422A1 (de) 1969-04-10
GB1033253A (en) 1966-06-22
BE633281A (fr) 1963-12-05
BR6349521D0 (pt) 1973-07-03
US3206470A (en) 1965-09-14
ES288785A1 (es) 1963-11-16

Similar Documents

Publication Publication Date Title
BE616548R (cs)
BE613319A (cs)
BE615804A (cs)
BE489310A (cs)
BE538252A (cs)
BE538831A (cs)
BE541929A (cs)
BE553896A (cs)
BE559145A (cs)
BE586180A (cs)
BE592434A (cs)
BE599783A (cs)
BE604335A (cs)
BE608197A (cs)
BE609543A (cs)
BE612190A (cs)
BE612311A (cs)
BE612464A (cs)
BE616785A (cs)
BE612926A (cs)
BE613108A (cs)
BE613190A (cs)
BE613298A (cs)
BE616909A (cs)
BE380301A (cs)